[SURTAVI] Sub-study of neurological events: more evidence in favor of TAVR

Courtesy of SBHCI.

The occurrence of a periprocedural neurological events is associated to an increased risk of death and morbidity at long term, both for transcatheter aortic valve replacement (TAVR) and for surgery.

SENTINEL Study: Cerebral Protection During TAVRThe SURTAVI study, recently presented at the ACC meeting and simultaneously published by NEJM, showed that TAVR with self-expandable CoreValve or Evolut R, is not inferior to surgery as regards all- cause mortality or disabling stroke in patients at moderate risk, at 2 year follow up.

 

All patients suspected of a neurological events were assessed with mini mental test and NIH scale.

 

At 30 days, a lower rate of neurological events was observed with TAVR vs. surgery (3.3% vs. 5.4%; p=0.031). This difference in favor of TAVR was maintained at 2 year follow up, though it was not as significant (6.3% vs. 8.0%, p=0,143).

 

Most of neurological events occurred within the first days after procedure. This was especially true for TAVR, where most occurred within 24 hrs, (while surgery continued to show events until day 4).

 

Conclusion

The incidence of early neurological events was lower in patients undergoing TAVR compared to patients undergoing surgery. Those presenting neurological events, (apart from the treatment group) required longer times of intensive care, hospitalization and were more often referred to rehabilitation centers.

 

Courtesy of SBHCI.

 

Dr. Pieter Kappetein
Dr. Pieter Kappetein.

Original Title: Neurological complications after transcatheter aortic valve implantation with a self- expanding bioprosthesis or surgical aortic valve replacement in patients at intermediate-risk for surgery.

Presenter: A. Pieter Kappetein.

 

 

KappeteinA.Pieter


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....